- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Laurie H. Sehn, MD | Authors
Laurie H. Sehn, MD, on the Key Takeaways From the GO29365 Study in DLBCL
December 31, 2020
The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.
Laurie H. Sehn, MD, on the Impact of Additional Findings From the GO29365 Study in DLBCL
December 24, 2020
Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.
Laurie H. Sehn, MD, Discusses Preliminary Findings From the GO29365 Study in DLBCL
December 08, 2020
The preliminary findings of the extension arm of the phase 2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) for patients with diffuse large B cell lymphoma.